Cover Image
市場調查報告書

酪胺酸蛋白激酶JAK3:開發中產品分析

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 367828
出版日期 內容資訊 英文 100 Pages
訂單完成後即時交付
價格
Back to Top
酪胺酸蛋白激酶JAK3:開發中產品分析 Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 100 Pages
簡介

本報告提供以酪胺酸蛋白激酶JAK3為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

酪胺酸蛋白激酶JAK3 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥開發企業

  • Aclaris Therapeutics, Inc.
  • Advinus Therapeutics Ltd
  • Arrien Pharmaceuticals, LLC
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb Company
  • Chipscreen Biosciences Ltd
  • Creabilis SA
  • F. Hoffmann-La Roche Ltd.
  • Ligand Pharmaceuticals, Inc.
  • MYOS RENS Technology Inc.
  • Pfizer Inc.
  • Portola Pharmaceuticals, Inc.
  • Principia Biopharma Inc.
  • Rigel Pharmaceuticals, Inc.
  • Theravance Biopharma, Inc.
  • Vectura Group Plc

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0401TDB

Summary

Global Markets Direct's, 'Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Pipeline Review, H2 2016', provides in depth analysis on Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)
  • The report reviews Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) Overview
    • Therapeutics Development
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Products under Development by Stage of Development
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Products under Development by Therapy Area
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Products under Development by Indication
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Products under Development by Companies
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
    • Aclaris Therapeutics, Inc.
    • Advinus Therapeutics Ltd
    • Arrien Pharmaceuticals, LLC
    • Astellas Pharma Inc.
    • Bristol-Myers Squibb Company
    • Chipscreen Biosciences Ltd
    • Creabilis SA
    • F. Hoffmann-La Roche Ltd.
    • Ligand Pharmaceuticals, Inc.
    • MYOS RENS Technology Inc.
    • Pfizer Inc.
    • Portola Pharmaceuticals, Inc.
    • Principia Biopharma Inc.
    • Rigel Pharmaceuticals, Inc.
    • Theravance Biopharma, Inc.
    • Vectura Group Plc
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Drug Profiles
    • ARN-4079 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATI-50001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATI-50002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cerdulatinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CS-510 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CS-944X - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CT-340 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Inhibit JAK3 for Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • peficitinib hydrobromide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PNQ-401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-348 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit JAK3 for Heart Transplantation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule To Inhibit JAK3 for Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit JAK 3 for Inflammation and Autoimmune Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit JAK3 for Alopecia and Dermatological Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Janus Kinase 3 for Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TD-1473 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tofacitinib citrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VR-588 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Dormant Projects
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Discontinued Products
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Featured News & Press Releases
    • Jun 09, 2016: Theravance Biopharma Reports Positive Results From Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor
    • Jun 08, 2016: Pfizer Research Advances Body Of Evidence For Tofacitinib Citrate (XELJANZ) Providing Clinicians With Additional Information For The Treatment Of Moderate To Severe RA
    • Jun 07, 2016: Pfizer Announces Positive Top-Line Results From Second Phase 3 Trial Of Oral XELJANZ (Tofacitinib Citrate) In Adults With Psoriatic Arthritis
    • Jun 01, 2016: Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings
    • Apr 14, 2016: Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016
    • Apr 05, 2016: Pfizer Announces Positive Top-Line Results From The First Phase 3 Trial Of Investigational Tofacitinib In Adults With Psoriatic Arthritis
    • Mar 23, 2016: Pfizer Announces European Medicines Agency Accepted For Review Its Marketing Authorization Application For Xeljanz (Tofacitinib Citrate) For The Treatment Of Moderate To Severe Rheumatoid Arthritis
    • Mar 18, 2016: Pfizer Announces Oral Tofacitinib, An Investigational Jak Inhibitor, Meets Primary And Key Secondary Endpoints In Two Pivotal Phase 3 Ulcerative Colitis Trials
    • Mar 18, 2016: Theravance Biopharma Presents Positive Results From a Preclinical Colitis Model for TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor
    • Mar 16, 2016: Pfizer To Present New Data On Investigational Tofacitinib In Inflammatory Bowel Disease At The 11th Congress Of ECO
    • Dec 10, 2015: Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase Inhibitor
    • Dec 10, 2015: Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase Inhibitor
    • Dec 05, 2015: Portola Pharmaceuticals Announces Cerdulatinib Data Presentation at the 2015 American Society of Hematology Annual Meeting and Exposition
    • Nov 02, 2015: New Data Continue to Characterize the Safety and Efficacy of XELJANZ in the Treatment of Rheumatoid Arthritis
    • Nov 02, 2015: Theravance Biopharma Submits Investigational New Drug Application for TD-1473, a GI-Targeted Pan-Janus Kinase Inhibitor
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Aclaris Therapeutics, Inc., H2 2016
  • Pipeline by Advinus Therapeutics Ltd, H2 2016
  • Pipeline by Arrien Pharmaceuticals, LLC, H2 2016
  • Pipeline by Astellas Pharma Inc., H2 2016
  • Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Pipeline by Chipscreen Biosciences Ltd, H2 2016
  • Pipeline by Creabilis SA, H2 2016
  • Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Pipeline by Ligand Pharmaceuticals, Inc., H2 2016
  • Pipeline by MYOS RENS Technology Inc., H2 2016
  • Pipeline by Pfizer Inc., H2 2016
  • Pipeline by Portola Pharmaceuticals, Inc., H2 2016
  • Pipeline by Principia Biopharma Inc., H2 2016
  • Pipeline by Rigel Pharmaceuticals, Inc., H2 2016
  • Pipeline by Theravance Biopharma, Inc., H2 2016
  • Pipeline by Vectura Group Plc, H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Dormant Projects (Contd..2), H2 2016
  • Dormant Projects (Contd..3), H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top